The 20-strain pneumococcal vaccine, produced by Pfizer Pharmaceutical Group (USA), was launched and deployed by VNVC for adults aged 18 and over, helping to effectively prevent 20 strains of pneumococcal bacteria that cause many serious diseases such as septic pneumonia, meningitis, sepsis, otitis media, sinusitis and other pneumococcal diseases.

The vaccine is produced at a modern factory in Belgium with advanced technology, creating a high immune response, long-term protection, and reducing the rate of healthy people carrying the bacteria, thereby limiting the spread in the community. This vaccine has been used in nearly 50 developed countries such as the US, UK, Germany, France, and Australia, proving its effectiveness in reducing the incidence and mortality of pneumococcal disease in adults.

Pneumococcus is the leading cause of many serious respiratory diseases and high mortality, especially in the elderly and people with underlying diseases. New vaccines with modern technology help expand the scope of protection and reduce booster doses, reducing vaccination and treatment costs caused by pneumococcus.

Compiled by: Le Minh Dat (email: lmd@vpha.org.vn)

____________________________________________

For more information, please visit the website of the VNVC vaccination center: https://vnvc.vn/vac-xin-prevenar-20/